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Transforming  growth  factor  β  (TGFβ)  is  a  pluripotent  cytokine  promoting  epithelial  cell 
plasticity during morphogenesis and tumour progression. TGFβ binding to type II and type I 
serine/threonine kinase receptors (TβRII and TβRI) causes activation of different intracellular 
signaling pathways. TβRI is associated with the ubiquitin ligase tumor necrosis factor receptor 
(TnFR)-associated factor 6 (TRAF6). Here we show that TGFβ, via TRAF6, causes Lys63-
linked  polyubiquitination  of  TβRI,  promoting  cleavage  of  TβRI  by  TnF-alpha  converting 
enzyme (TACE), in a PKCζ-dependent manner. The liberated intracellular domain (ICD) of 
TβRI associates with the transcriptional regulator p300 to activate genes involved in tumour 
cell invasiveness, such as Snail and MMP2. moreover, TGFβ-induced invasion of cancer cells 
is TACE- and PKCζ- dependent and the TβRI ICD is localized in the nuclei of different kinds of 
tumour cells in tissue sections. Thus, our data reveal a specific role for TβRI in TGFβ mediated 
tumour invasion. 
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T
ransforming  growth  factor  β  (TGFβ)  is  a  cytokine  which 
plays an important role during normal embryogenesis due to 
its multifunctional effects on cellular responses such as pro-
liferation, differentiation, apoptosis and migration. In recent years 
TGFβ has become recognized as a potent regulator of cellular plas-
ticity which is a central event during embryogenesis and tumour 
progression. TGFβ signals through its binding to the type II and type 
I serine/threonine kinase receptors (TβRII and TβRI, respectively), 
to cause their hetero-oligomerization which subsequently activates 
different intracellular signaling pathways. TβRI phosphorylates the 
latent transcription factors Smad2 and Smad3 in early endosomes, 
to induce complex formation with Smad4 and nuclear transloca-
tion to regulate target genes1–4. TβRI has been found to harbour a 
consensus binding site for the ubiquitin ligase tumor necrosis factor 
receptor (TNFR)-associated factor 6 (TRAF6); upon TGFβ bind-
ing TRAF6 activates the TGFβ activated kinase 1 (TAK1)—p38 
mitogen activated protein (MAP) kinase pathway5,6. Interestingly, 
TNF-alpha converting enzyme (TACE) has recently been shown to 
cleave TβRI in its extracellular domain, which was demonstrated to 
cause a loss of TGFβ-induced inhibition of proliferation of cells7.
Posttranslational modifications of proteins, such as monoubi-
quitination or Lys63-linked polyubiquitination, have emerged as 
an important mechanism to control the localization or function of 
the protein, whereas Lys48-linked polyubiquitination of proteins 
instead targets its substrate for proteasomal degradation8,9. TRAF6 
is known to induce Lys63-linked polyubiquitination of its substrates, 
including TAK15.
The underlying molecular mechanisms for how TGFβ can both 
act as a tumour suppressor and a promoter remain to be fully under-
stood. To further address how TGFβ promotes tumour progression, 
we have investigated the possibility that TRAF6 regulates the sub-
cellular localization of TβRI by Lys63-dependent polyubiquitina-
tion and whether this is related to the capability of TGFβ to facilitate 
tumour invasion. We report here that TGFβ uses TRAF6, PKCζ and 
TACE to promote the formation of an intracellular domain (ICD) 
of the TβRI that is translocated to the nucleus, where it promotes 
tumour invasion by induction of Snail and MMP2.
Results
Nuclear accumulation of the intracellular domain of TRI. To 
investigate whether TβRI is proteolytically cleaved in human prostate 
cancer (PC-3U) cells, we ectopically expressed a C-terminally tagged 
constitutively active (ca) TβRI (HA-ALK5TD). Notably, in addition 
to the full length receptor, the HA antibody recognized a smaller 
fragment, corresponding to the estimated size of the intracellular 
part of TβRI (Supplementary Fig. S1a). Using immunofluorescence 
and  confocal  microscopy,  we  next  investigated  the  subcellular 
localization of endogenous TβRI in PC-3U cells visualized by a 
antibodies  raised  against  its  intracellular,  C-terminal  part  (V22) 
or its extracellular N-terminal part (H100; Fig. 1a). An enhanced 
nuclear  accumulation  of  TβRI,  or  its  C-terminal  fragment,  was 
noticed in TGFβ-stimulated PC-3U cells, upon staining with the 
V22 antibody. In contrast, immunofluorescence staining revealed 
that the extracellular domain of the receptor, visualized by the H100-
antibody was mainly localized in the cell membrane in PC-3U cells 
stimulated with TGFβ for 6 h (Fig. 1a). To ensure the specificity of 
the  V22  antibody  in  immunofluorescence  and  immunoblotting, 
siRNA was used to knock-down endogenous TβRI expression in 
PC-3U cells (Fig. 1a and Supplementary Fig. S1b); qRT-PCR was 
also used to demonstrate a substantial decrease of TβRI mRNA 
expression  (Supplementary  Fig.  S1b).  The  specificity  of  the  V22 
antibody used in our study was also verified by peptide blocking 
(Supplementary Fig. S1c).
To further validate the observation that TβRI, or its intracellular 
domain (ICD), is translocated to the nucleus in a TGFβ-depend-
ent  manner,  we  performed  a  nuclear  fractionation  assay  of  cell 
lysates from TGFβ-treated PC-3U cells. Immunoblotting of nuclear 
extracts by the V22 antibody revealed a TβRI fragment of approxi-
mally  34 kDa,  which  was  not  recognized  by  the  H100  antibody 
raised against the N-terminal part of TβRI (Fig. 1b). In contrast, 
full-length TβRI was observed in the cytoplasmic fraction, both by 
the V22 and H100 antibodies (Fig. 1b). While a pronounced increase 
of nuclear TβRI was detected by immunofluorescence only after 
TGFβ stimulation (Fig. 1a), nuclear TβRI was detected by immu-
noblotting also in the absence of TGFβ stimulation (Fig. 1b). This 
discrepancy is probably due to the fact that sensitivity for detection 
of nuclear TβRI is higher with the nuclear fractionation assay. To 
further investigate the TGFβ-dependency of nuclear accumulation 
of TβRI, we expressed a fusion protein in which GFP was linked to 
the C-terminal part of TβRI in PC-3U cells. The GFP-tagged TβRI 
entered the nucleus of PC-3U cells after stimulation with TGFβ for 
6 h, while GFP expressed from a vector containing GFP alone did 
not (Fig. 1c). We also investigated the nuclear localization of ectopi-
cally expressed C-terminally HA-tagged ca TβRI in PC-3U cells 
and observed a TGFβ-induced accumulation of the HA-tagged ca 
TβRI-ICD (Supplementary Fig. S1d). This observation is consistent 
with the nuclear accumulation of endogenous TβRI-ICD as shown 
in Figure 1a,b. In further support of the notion that the N-termi-
nal part of the TβRI did not enter the nucleus, a HA-tagged TβRI 
with the tag localized N-terminally between amino acid residues 27 
and 284, was found not to enter the nucleus in PC-3U cells with or 
without treatment with TGFβ (Supplementary Fig. S1e). Moreover, 
no TGFβ-induced increase of the TβRI-ICD for N-terminal HA-
tagged  TβRI  was  observed  (Supplementary  Fig.  S1f).  Together, 
these results suggest that the ICD of TβRI enters into the nucleus in 
PC-3U cells in response to TGFβ stimulation.
Nuclear accumulation of TβRI is dependent on TRAF6. We have 
recently identified a consensus binding site for TRAF6 in TβRI5. Lig-
and-induced oligomerization of the TGFβ receptor complex results 
in receptor kinase-independent activation of the enzymatic activ-
ity of TRAF6. This in turn causes Lys63-polyubiquitin-dependent 
activation of TGFβ-activated kinase-1 (TAK1), causing activation 
of p38 MAPK in PC-3U cells. In contrast, activation of the canoni-
cal Smad pathway does not require TRAF65. To examine whether 
TRAF6 is important for the cleavage and nuclear accumulation of 
TβRI, we expressed C-terminally HA-tagged wild-type (wt) caTβRI 
(HA-TβRI)  or  the  HA-tagged  caE161A  (HA-E161A)  receptor 
mutant which is unable to bind TRAF6, but still causes activation 
of the canonical Smad signalling pathway5. As shown in Figure 2a, 
stimulation of cells with TGFβ resulted in Lys63-linked polyubiqui-
tination of wt TβRI, but not of the E161A mutant TβRI. Cleavage of 
the wt TβRI, as observed by immunoblotting of total cell lysate with 
HA antiserum was found to associate with its Lys63-linked poly-
ubiquitination (Fig. 2a). Moreover, the E161A mutant TβRI failed 
to activate the p38 MAPK pathway while it was still able to activate 
Smad2, consistent with our previous report5 (Fig. 2a). In addition, 
knock-down of endogenous TRAF6 in PC-3U cells by siRNA, also 
resulted in loss of Lys63-linked polyubiquitination of TβRI, as well 
as loss of the formation of the TβRI ICD in response to stimula-
tion with TGFβ (Supplementary Fig. S2a,b). By using either Lys63 
or Lys48 polyubiquitin-specific antibodies, we found that wt TβRI 
was  Lys63-polyubiquitinated  after  30 min  of  TGFβ  stimulation, 
while no obvious sign of TGFβ-induced Lys48-polyubiqutination   
of  TβRI,  was  observed  in  this  cell  line  during  this  time  course   
(Fig. 2a and Supplementary Fig. S2a,c).
The pattern of polyubiquitination of TβRI was further examined 
using HA-tagged wt or mutant ubiquitin overexpressed in PC-3U 
cells. TGFβ stimulation induced polyubiquitination of TβRI in PC-
3U cells transiently transfected with a ubiquitin mutant in which all 
lysine residues where mutated except Lys63, while reduced ubiq-
uitination was seen when a similar mutant retaining only Lys48 ARTICLE     
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was expressed (Fig. 2b). In addition, TRAF6 was shown to induce   
the polyubiquitination of TβRI in an in vitro ubiquitination assay, 
providing  firm  evidence  that  TβRI  is  a  substrate  for  TRAF6   
(Supplementary Fig. S3).
TGFβ-induced  nuclear  accumulation  of  ectopically  expressed 
C-terminal  HA-tagged  caTβRI  in  PC-3U  cells  occurred  more   
efficiently for the wt TβRI than for the E161A mutant HA-TβRI, 
as  analyzed  by  immunofluorescence  (Fig.  2c).  On  the  basis  of 
these  data,  we  conclude  that  TRAF6  causes  Lys63-dependent 
polyubiquitination of TβRI in a TGFβ-dependent manner which   
correlates with generation of an intracellular fragment of TβRI and 
its nuclear accumulation.
TβRI is cleaved by TACE. The metalloproteases TNF-alpha con-
verting enzyme (TACE)/ADAM17 and ADAM10, when activated, 
cleave certain receptors and adhesion proteins, just outside the 
cell membrane. TACE has recently been shown to cleave TβRI in 
an ERK MAP-kinase dependent manner, leading to desensitiza-
Merge
DAPI
*
IB: TβRI
IB: TβRI
0
10
20
30
40
50
60
70
80
GFP-TβRI
GFP
TGFβ  6h
+
+
+
+
+ –
–
– –
–
–
90
+
GFP-TβRI
GFP GFP-TβRI
Merge
DAPI
Merge
DAPI
TβRI
(V22)
TβRI
(H100)
Merge
DAPI
TβRI siRNA Control siRNA
TGFβ 6 h – TGFβ 6 h –
GFP
TGFβ 6 h – TGFβ 6 h –
TGFβ (h) 6 0.5 0 6 0.5 0
TβRI-FL
TβRI-ICD
TβRI-FL
β-Tubulin
Lamin A
Nuclear Cytoplasmic
kDa
53
34
53
34
50
70
C
e
l
l
s
 
w
i
t
h
 
T
β
R
I
 
i
n
 
t
h
e
 
n
u
c
l
e
u
s
 
(
%
)
(V22)
(H100)
Figure 1 | TGF induces nuclear accumulation of TRI intracellular domain (TRI-ICD). (a, b) Knockdown of TβRI by siRnA was performed to 
demonstrate the specificity of the V22 and H100 antibodies, which recognize the intracellular and extracellular domain of TβRI, respectively, in 
immunofluorescence (a; DAPI was used to visualize cell nuclei, scale bar 20 µm). (b) Cell lysates of PC-3u cells treated or not with TGFβ, were 
fractionated into cytoplasmic and nuclear proteins and subjected to sDs–gel electrophoresis, followed by immunoblotting using V22 and H100  
antibodies. β-tubulin and lamin A served as controls for the cytoplasmic and nuclear fractions, respectively. molecular weight markers are indicated.  
(c) Representative confocal microscopy pictures of C-terminally pEGFP-n3-tagged wt TβRI (GFP- TβRI) and pEGFP-n3-vector (GFP) expressed in PC-
3u cells treated with TGFβ for 6 h are shown (left panel) and quantified in right panel (mean ± s.d., n = 3–5 independent experiments where N = 350 cells 
where counted in each group, *P < 0.0002, AnoVA). Cell nuclei were stained with DAPI. scale bar 20 µm.ARTICLE
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tion of TGFβ signaling7. TACE is often overexpressed in tumours 
and is activated by PKC10. To further characterize the molecular 
mechanisms  behind  the  cleavage  and  nuclear  translocation  of 
TβRI, we examined the possible involvement of the metallopro-
teinase TACE/ADAM17. Treatment of human PC-3U cells with 
TPA to activate PKC10 led to nuclear accumulation of endogenous 
TβRI  or  its  ICD,  as  shown  by  immunofluorescence  (Fig.  3a). 
Moreover, when PC-3U cells expressing the C-terminally tagged 
HA-caTβRI were treated with TGFβ or TPA, the ICD accumu-
lated in the nuclear fraction (Fig. 3b). Pretreatment of cells with 
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Figure 2 | TRAF6 promotes Lys63-dependent polyubiquitination of wt TRI but not of the E161A mutant TRI. (a) PC-3u cells transiently transfected 
with C-terminally HA-tagged wt TβRI, or E161A mutant TβRI deficient in association with TRAF6, were treated or not with TGFβ, whereafter ubiquitination 
of TβRI was examined by an in vivo ubiquitination assay. Complexes immunoprecipitated (IP) with anti-HA antibodies were immunoblotted (IB) with 
Lys63 (K63)-linked polyubiquitin-specific antibody. A light-chain specific secondary antiserum was used to avoid cross-reaction with IgG heavy chain. 
molecular weight markers are indicated. Another part of the corresponding total cell lysates (TCL) was subjected to immunoblotting for HA to detect 
the TβRI-ICD fragment, and activation of p38 and smad2, by phospho-specific antisera. The filters were then reprobed with total p38 or smad2, to verify 
specificity of phospho-specific antisera and actin served as internal control for equal loading of proteins. (b) In vivo ubiquitination assays performed in PC-
3u cells transiently transfected with HA-tagged wt, K63- and K48-only ubiquitin. Cell lysates were immunoprecipitated with V22 antibody against TβRI, 
and K63-dependent polyubiquitination was visualized by immunoblotting with P4D1-antiserum. A light-chain specific secondary antiserum was used 
to avoid cross-reaction with IgG heavy chain. The TCL-filter was subjected to immunoblotting with an HA-antibody to verify equal expression levels of 
ubiquitin. (c) PC-3u cells ectopically expressing C-terminally HA-tagged wt TβRI or the corresponding E161A mutant were stimulated with TGFβ for 0.5 h 
and thereafter stained with an HA antibody. staining with DAPI was used to visualize cell nuclei. scale bar 20 µm.ARTICLE     
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TAPI-2, an inhibitor of TACE, led to a decreased nuclear entrance 
of the ICD of endogenous TβRI in response to TGFβ stimulation 
(Fig. 3c,d). As TACE was shown recently to associate with the 
ectopically expressed TβRI in cells expressing HER211, we inves-
tigated by co-immunofluorescence if endogenous TβRI associ-
ated with TACE in PC-3U cells. A TGFβ-induced colocalization   
of  TβRI  and  TACE  was  observed  (Fig.  3e).  From  these  data, 
we conclude that activation of TACE, either by TPA-treatment 
of cells or stimulation with TGFβ, leads to accumulation of the 
TβRI ICD in the nucleus.
Determination of the TACE cleavage site in TβRI. Previous stud-
ies have shown that TACE has a strong preference for cleavage at 
Ala-Val  sequences12  or  Gly-Leu  sequences13.  TβRI  contains  two 
Gly-Leu sequences, located at position Gly52 and Gly120. To inves-
tigate the possibility that TACE cleaves TβRI at Gly120, which is 
located close to the transmembrane domain, we mutated Gly 120 
to Ile (G120I) in TβRI. The G120I mutant TβRI did not undergo 
cleavage  in  response  to  TGFβ  stimulation  (Fig.  4a),  suggesting 
that TACE cleaves TβRI at the Gly-Leu bond at position 120–121. 
The kinase activity of the G120I mutant was intact as judged by its   
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Figure 3 | TACE regulates nuclear accumulation of TRI ICD. (a) PC-3u cells were treated with TPA for 6 h. Endogenous TβRI is shown by 
immunofluorescence using the V22 antibody. Quantification of the number of cells showing endogenous TβRI in the nucleus is shown on the right side 
of the panel (mean ± s.d., n = 3 independent experiment, where N = 200–300 cells where counted in each group, *P < 0.0001, AnoVA). scale bar 20 µm. 
(b) nuclear proteins from PC-3u cells transiently transfected with C-terminally HA-tagged TβRI were treated as indicated, then samples were subjected 
to immunoprecipitation with an HA antibody. The TβRI-ICD was visualized by immunoblotting with an HA antibody and the membrane was thereafter 
stripped and reblotted with VPn antiserum against the intracellular part of the receptor. (c) PC-3u cells were treated with either TGFβ or TPA alone for 
6 h or with both TGFβ and TAPI-2 for 6 h. Endogenous TβRI is shown by immunofluorescence using the V22 antibody. Quantification of the number of 
cells showing endogenous TβRI in the nucleus is shown on the right side of the panel (mean ± s.d, n = 3 independent experiments, where N = 200–300 cells 
where counted from each group, *P < 0.0001, AnoVA). scale bar 20 µm. (d) Cell lysates of PC-3u cells treated with TGFβ in the presence or absence of 
TAPI-2 as indicated, were fractionated into cytoplasmic and nuclear proteins and subjected to sDs-gel electrophoresis, followed by immunoblotting using 
V22 antibody, which recognizes both the TβRI full length (TβRI-FL) and intracellular domain of TβRI (TβRI-ICD). β-tubulin and lamin A served as controls 
for the cytoplasmic and nuclear fractions, respectively. molecular weight markers are indicated. *indicates a background band. (e) PC-3u cells were with 
treated or not with TGFβ for 0.5 h. Endogenous TACE and TβRI are shown by co-immunofluorescence using TACE (TRITC) and V22 (FITC) antisera. Their 
colocalization is demonstrated by the yellow colour as shown in merge. The pictures are enlargements of the picture to the right (white box). scale bar 
20 µm. stainings with DAPI was used to visualize cell nuclei in (a, c and e).ARTICLE
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ability  to  phosphorylate  Smad2,  when  compared  with  wt  TβRI. 
Moreover,  the  G120I  mutant  TβRI  did  not  accumulate  in  the 
nucleus in response to TGFβ stimulation (Fig. 4b).
PKCζ is needed for TACE-induced cleavage of TβRI. We next 
investigated whether PKCζ, which is the only member in the PKC-
family known to form a multiprotein-complex with TRAF614, is 
involved in cleavage of TβRI and nuclear translocation of the ICD. 
Inhibition  of  PKCζ,  by  PKCζ  pseudosubstrate,  completely  pre-
vented nuclear accumulation of the TβRI ICD in a dose-dependent 
manner (Fig. 5a and Supplementary Fig. S4a). It is well accepted 
that the classical members of the PKC family are activated by TPA, 
while atypic PKC isoforms like PKCζ are thought not to be activated 
by TPA15,16. However, we found that PKCζ is activated as a result 
of stimulation of cells by TGFβ, as well as by TPA (Fig. 5b). TGFβ 
stimulation did not lead to activation of PKCζ in TRAF6 − / −  MEFs 
(Fig. 5c), supporting the notion that TRAF6 is important for TGFβ-
induced activation of PKCζ. Using a nuclear fractionation assay, we 
noticed a significant loss of TGFβ-induced nuclear accumulation 
of TβRI ICD after siRNA-mediated silencing of PKCζ (Fig. 5d). In 
addition, ectopic expression of wt PKCζ promoted expression and 
cleavage of caTβRI or kinase dead (KD) TβRI mutant (Fig. 5e).   
Treatment of PC-3U cells with the PKCζ inhibitor decreased the 
formation of the ICD of C-terminally HA-tagged ca TβRI in TGFβ-
treated cells as well as in a dose-dependent manner (Supplemen-
tary Fig. S4b,c), while treatment with the TβRI kinase inhibitor 
SB505124 had no major effect (Fig. 5f).
Using  immunofluorescence  stainings,  we  observed  TGFβ-
induced co-localization of endogenous TβRI and TACE. Adding 
the  PKCζ  pseudosubstrate  to  cells  prevented  the  co-localization 
(Fig.  5g),  suggesting  that  PKCζ  activity  is  needed  for  a  proper 
localization of TβRI to a subcellular compartment where it can be 
cleaved by TACE. In conclusion, TGFβ causes activation of PKCζ in 
a TRAF6-dependent manner, which is important for the proteolytic 
cleavage of the TβRI by TACE, leading to nuclear accumulation of 
TβRI ICD.
TβRI ICD regulates transcription. The observation that the ICD 
of TβRI enters the nucleus in TGFβ-treated PC-3U cells, suggests 
that it might participitate in gene regulation. To search for a link 
between the nuclear TβRI ICD and gene transcription, we investi-
gated if TβRI ICD associates with the well-known transcriptional 
regulator p300. TGFβ treatment of PC-3U cells led to a co-localiza-
tion of TβRI and p300 in nuclear specles (Fig. 6a), which we identi-
fied by co-immunofluorescence as promyelocytic leukemia protein 
(PML) nuclear bodies17 (Fig. 6b). Treatment of cells with the PKCζ 
pseudosubstrate prevented the co-localization of TβRI with PML 
nuclear bodies (Fig. 6b). By co-immunoprecipitation experiments, 
the acetyltransferase p300 was found to associate with TβRI ICD 
in vivo (Fig. 6c,d) and we used an acetyl-lysine antibody to verify 
that TβRI ICD is acetylated (Fig. 6e). In contrast, in cells expressing 
the E161A mutant TβRI, less ICD was associated with endogenous 
p300 and less acetylated ICD was detected (Fig. 6d,e). We observed 
that the level of p300 was lower in cells transfected with the E161A 
mutant TβRI unable to bind TRAF6, compared to wt TβRI (Fig. 6d). 
Using qRT-PCR, a TGFβ-induced increase of p300 mRNA expres-
sion was observed in cells transiently transfected with wt TβRI, but 
not in cells transfected with E161A mutant TβRI (Fig. 6f). This sug-
gests that TGFβ induces p300 in a TRAF6-dependent manner.
Next, we used qRT-PCR to analyze the effect of TβRI ICD on 
known TGFβ target genes. Snail and MMP2 mRNA expressions 
were induced by wt TβRI but much less by the E161A mutant TβRI, 
whereas PAI1 and Smad7 were induced by both wt and E161A 
mutant TβRI (Fig. 6g). A chromatin immunoprecipitation (ChIP) 
assay revealed binding of TβRI or TβRI ICD to the endogenous 
Snail promoter in a TGFβ-dependent manner in PC-3U cells (Fig. 
6h). Since expression of Snail and MMP2 genes is linked to tumour 
invasiveness18, we examined PC-3U cells expressing wt or E161A 
mutant TβRI using an invasion assay. Interestingly, we observed 
that TGFβ-induced invasion occurred in PC-3U cells only when 
wt TβRI was expressed, whereas epidermal growth factor (EGF) 
stimulated invasion both in cells expressing wt or mutant TβRI 
(Fig. 6i, right panel shows optical density (OD) mean values of 
stained invasive tumour cells). Similar results were observed when 
the experiment was repeated using the human prostate cancer cell 
line LNCaP; TGFβ treatment of LNCaP cells expressing wt TβRI, 
but not the E161A mutant TβRI, promoted their invasion (Sup-
plementary Fig. S5a,b). Thus, our data propose that the TβRI ICD 
associates with p300 in nuclear PML bodies in a PKCζ-dependent 
manner, and is acetylated by p300. Moreover, Snail and MMP2 are 
induced by TβRI ICD, correlating with an increased invasiveness 
of cells.
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Nuclear TRI ICD is observed in malignant prostate cells. We 
observed that the nuclear entrance of TβRI was associated with 
invasiveness of prostate cancer cells; therefore, we used immun-
ofluorescence and confocal microscopy to investigate the subcel-
lular localization of endogenous TβRI, in primary human pros-
tate epithelial cells (PrEC) cells and PC-3U cells, visualized by 
the V22 antibody raised against its C-terminal part (Fig. 6j,k). 
Intriguingly, accumulation of TβRI or its ICD in the nucleus took 
place in malignant PC-3U cells, but not in normal PrEC cells, 
where TβRI was retained in cell-cell contacts, also after treatment 
with TGFβ.
Nuclear TRI ICD is linked to TGF-induced cancer invasion. 
To explore the generality of the TGFβ-induced pathway identified 
in this report, we extended our investigation to the human breast 
carcinoma cell line MDA-MB-231 and the human lung carcinoma 
cell line A549. By using confocal imaging, we found that TGFβ 
treatment of MDA-MB-231 also promotes accumulation of endog-
enous ICD of TβRI in the nucleus, in a TACE- and PKCζ- depend-
ent  manner,  which  was  found  to  be  associated  with  the  TGFβ-
induced invasiveness of the cells (Fig. 7a,b). We observed a similar 
association between TGFβ-induced nuclear accumulation of TβRI 
ICD and TGFβ-induced invasiveness in the A549 cell line, which 
also in these cancer cells were regulated by TACE and PKCζ (Fig. 
7c,d). From these data we conclude that TGFβ-induced invasion of 
human breast and lung cancer cells correlates with nuclear accumu-
lation of TβRI in a TACE- and PKCζ-dependent manner.
Nuclear TRI ICD is observed in human tumours in vivo. To 
explore whether nuclear accumulation of the TβRI ICD occurs 
in human tumours, we used immunohistochemistry to investi-
gate the expression and localization of TβRI in a panel of pros-
tate cancers, renal cell carcinomas and bladder tumours. Nuclear 
accumulation of TβRI ICD was observed in 19 of 19 investigated 
prostate cancer tissues, in 19 of 24 renal cell carcinomas, and in 
21 of 23 bladder tumours, while staining with the H100 antibody 
to visualize the extracellular part of TβRI, showed staining only 
in the cytoplasm (Fig. 8). No immunohistochemical staining of 
TβRI  was  observed  in  control  experiment  (when  the  primary 
antibodies were omitted, Supplementary Fig. S6). Thus, our data 
demonstrated that nuclear accumulation of TβRI ICD is observed 
in human tumours.
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Figure 6 | TRI promotes expression of Snail and invasion of prostate cancer cells in a TGF-dependent manner. (a) PC-3u cells were treated with 
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Discussion
We have provided evidence that TβRI undergoes cleavage by TACE 
in cancer cells and that the ICD of TβRI is translocated to the 
nucleus where it associates with the transcriptional regulator p300 
in nuclear PML bodies. Accumulation of the ICD of TβRI in the 
nucleus occurs after TGFβ stimulation and is dependent on TRAF6, 
TACE and PKCζ. The expression levels of Smads did not influence 
the PKCζ-dependent generation of the ICD of TβRI as knock down 
of Smad4 by siRNA, had no effect on the PKCζ-induced generation 
of TβRI ICD (Supplementary Fig. S7a). Neither did overexpression 
of Smad2, 3 or 4 in PC-3U cells affect PKCζ-induced generation 
of TβRI ICD (Supplementary Fig. S7b). Since the TRAF6-binding 
deficient TβRI mutant (HA-E161A) still activates Smad2, while gen-
eration of the TβRI ICD is impaired, it appears that the canonical 
Smad pathway can operate independently of the generation of the 
TβRI ICD, which instead correlates with activation of the TRAF6—
TAK1—p38 MAPK pathway (Fig. 2a).
Integrins are essential adhesion receptors which are involved in 
cell migration and extracelullar matrix assembly19. TGFβ-induced 
activation of the p38 MAPK pathway has been demonstrated to 
be related to integrin signaling and implicated in epithelial-mes-
enchymal transition in certain cell lines20. To investigate a possible 
relationship between integrin signaling and TGFβ-induced genera-
tion of TβRI ICD, we used antibodies which promotes or inhibits 
integrin activation21 (TS2 and CD29 antibodies, respectively). No 
major effects on TGFβ-induced formation of the TβRI ICD was 
observed, when integrins were activated or inhibited (Supplemen-
tary Fig. S8).
Exactly how TβRI ICD is translocated to the nucleus is the topic 
of our ongoing investigations. Interestingly, our finding that the 
ICD of TβRI associates with p300 and the Snail promoter, to sup-
port transcriptional regulation of a subset of genes, including Snail, 
MMP2 and p300, correlates with increased invasiveness of cells. 
Whether the Smad proteins also participitate in the transcriptional 
complexes is an interesting possibility that remains to be elucidated. 
Nuclear accumulation of TβRI was observed in prostate, breast and 
lung cancer cells and also in several cancer tissues, but not in pri-
mary prostate epithelial cells. Thus the pathway elucidated in this 
report occurs in different kinds of human tumours and could con-
tribute to tumour progression. Taken together, our data support the 
notion that the cleavage and nuclear accumulation of TβRI is part 
of a tumour promoting TGFβ signaling pathway.
Methods
Cell culture. The human prostate cancer cell lines PC-3U, originating from PC-322, 
which are known to produce TGFβ in an autocrine fashion23 and LNCaP, were pur-
chased from ATCC and grown in RPMI-1640 with 10% fetal bovine serum (FBS) 
and L-glutamine. Wt MEF and TRAF6 − / −  MEF were grown in Dulbecco’s modified 
Eagle’s medium (DMEM) containing 10% FBS. Normal human primary prostate 
epithelial cells (PrEC) were purchased from Cambrex Bio Science Walkersville. 
The cells were grown according to the manufacturer’s recommendation in Prostate 
Epithelial Cell Basal Medium supplemented with Clonetics PrEGM bullet kit. The 
cells were starved 12–18 h in medium supplemented with 1% FBS before TGFβ 
stimulation (TGFβ1 10 ng/ml (R&D System, UK).
Antibodies and reagents. Antibodies or antisera against the following proteins 
were used in immunoblotting or immunofluorescence (IF): HA (Y-11, 1:500 
and 1:50 for IF), ubiquitin (P4D1, 1:400), TβRI (V22, 1:250 and 1:50 for IF); the 
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Figure 7 | TRI nuclear localization in human breast and lung carcinoma cells is associated with tumour invasion. (a) Human breast carcinoma  
(mDA-mB-231) cells were starved and treated with TGFβ in the presence or absence of the PKCζ pseudosubstrate (P.s.) or TAPI-2, as indicated. 
Endogenous C-terminal TβRI was visualized by immunofluorescence using the V22 antibody (TRITC). Quantification of the number of cells showing 
endogenous TβRI in the nucleus is shown on the right side of the panel (mean ± s.d., n = 3 independent experiment, where N = 200–300 cells where counted 
in each group, *P < 0.001, AnoVA). scale bar 20 µm. (b) Invasion assay for mDA-mB-231 treated with TGFβ in the absence or presence of TAPI-2 and 
PKCζ P.s. Cells were visualized by staining with crystal violet cell stain solution. Right panel presents mean values for optical density (oD) of invasive cells. 
Error bars represents s.d. (n = 3 independent experiments, *P < 0.05; students t-test). (c) Human lung carcinoma (A549) cell were starved and treated with 
TGFβ in the presence or absence of the PKCζ P.s or TAPI-2, as indicated. Endogenous C-terminal TβRI was visualized by immunofluorescence using the 
V22 antibody (TRITC). Quantification of the number of cells showing endogenous TβRI in the nucleus is shown on the right side of the panel (mean ± s.d., 
n = 3 independent experiment, where n = 200-300 cells where counted in each group, *P < 0.0003, AnoVA). scale bar 20 µm. (d) Invasion assay for A549 
cells treated with TGFβ in the absence or presence of TAPI-2 and PKCζ P.s. Cells were visualized by staining with crystal violet cell stain solution. Right 
panel presents mean values for oD of invasive cells. Error bars represents mean ± s.d. (n = 3 independent experiments; *P < 0.05, **P < 0.002, AnoVA).ARTICLE
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specificity of this antibody has previously been reported24,25) and H100 (1:250), 
TRAF6 (D10, 1:500) and p300 (NM11, 1:200) antibodies were from Santa Cruz 
Biotechonology; p-Smad2 (1:500) and TβRI (VPN, 1:500) antisera were generated 
in rabbits in-house; lamin A (1:1,000), TACE/ADAM17 (1:50 for IF), pPKCζ/λ 
(Thr410/403, 1:1,000), PKCζ (1:1,000), p-p38 (1:1,000), p38 (1:1,000), Smad2 
(1:1,000) and acetyl-Lys antibodies (1:1,000) were from Cell Signaling. Antibody 
against TRAF6 C-term was from ZYMED Laboratories (1:500); UbK63 antibody 
(1:1,000) was from Enzo Life Sciences. UbK48 Clone Apu 207 antibody (1:1,000) 
was a kind gift from V.M. Dixit, Genetech; antibodies against β-actin (1:10,000), 
β-tubulin (1:1,000), HA (1:1,000) were from Sigma.
The mouse monoclonal TS2/16 antibody (a kind gift from Dr K. Rubin) was 
used at a concentration of 20 µg/ml to activate β1-integrin and a rat anti-human 
CD29 antiserum, purchased from BD Pharmingen, was used at a concentration 
of 10 µg/ml to inactivate β1-integrin respectively. Horseradish peroxidase-cou-
pled secondary antibodies were from Sigma. In some experiments, either goat 
anti-mouse IgG, light chain specific or mouse anti-rabbit IgG, light chain specific 
antisera from Jackson ImmunoResearch Laboratories, were used. 4,6-Diamidino-
2-phenylindole dihydrochloride (DAPI) fluorescent dye to visualize cell nuclei 
by microscopy was purchased from Merck and TRITC labelled phalloidin from 
Sigma. Alexafluor 555 was purchased from Invitrogen.
Protein-G Sepharose was from GE Healthcare; LumiLight Western blotting 
substrate and Pefabloc were from Roche, PageRuler prestained protein ladder was 
from Fermentas; TAPI-2 was from BIOMOL Research Laboratories Inc., and used 
at concentrations of 10–20 µM. PKCζ pseudosubstrate was from TOCRIS Bio-
science. The PKC activator phorbol 12-myristate 13-acetate (PMA, referred to as 
TPA in our paper) and a TβRI inhibitor (SB505124), were purchased from Sigma 
and used at concentrations of 100 nM and 10 µM, respectively. All inhibitors were 
added 1 h before TGFβ stimulation.
Protein analyses. The cells were starved for 12–18 h and then stimulated with 
TGFβ for indicated time periods, washed twice in ice-cold PBS and lysed in ice-
cold lysis buffer (150 mM NaCl, 50 mM Tris pH 8.0, 0.5% (v/v) DOC, 1% (v/v) 
NP40, 10% (v/v) glycerol, 1 mM aprotinin, 1 mM Pefabloc and 2 mM sodium 
orthovanadate). After centrifugation, supernatants were collected and protein 
concentrations were determined by BCA protein measurement kit (Nordic 
Biolabs). Equal amount of protein from total cell lysate and immunoprecipitation 
were run in SDS-PAGE using 6, 10, 12 or 4–12% gradient polyacrylamide gels, 
blotted on to polyvinylidine difluoride membranes and subjected to immuno-
blotting, as previously described25. In vitro and in vivo ubiquitination assays, 
immunofluorescence and transient transfections were performed, as previously 
described5,26,27. HA, TACE, H100 and V22 antibodies were diluted 1:50 when 
used for immunofluorescence. Photo micrographs were obtained by Zeiss 510 
Meta (Carl Zeiss Microimaging, Inc.) with a digital camera (RET-EXi-F-M-12-C) 
from Q-imaging.
Nuclear fractionation assays. Two different protocols for nuclear fractionation 
were used to examine TβRI accumulation in the nucleus in response to TGFβ.
The first used for cell fractionation, has earlier been described27 and was used in 
the experiments shown in Figures 1b and 5d.
The second was applied in experiments shown in Figure 3b and used Nuclear 
Complex Co-IP kit purchased from Active Motif. Cells in a 10-cm dish were 
washed twice with ice-cold PBS, and then scraped and collected into 1 ml ice-cold 
PBS; after centrifugation at 1,500 r.p.m. for 5 min at 4 °C, the cell pellet was gently 
resuspended in 500 µl Hypotonic Buffer and incubated on ice for 15 min. Twenty 
five µl of Detergent Solution was added and gently mixed and centrifuged at 
14,000×g for 30 s, at 4 °C. The nuclear pellet was resuspended in 100 µl Complete 
Digestion Buffer, vortexed gently for 2 s after adding 0.5 µl of Enzymatic Shearing 
Cocktail, thereafter incubated for 10 min at 37 °C. The nuclear lysates were vortexed 
gently after 2 µl of 0.5 M EDTA had been added to stop the reaction, and then 
incubated on ice for 5 min, centrifuged (14,000 g, 10 min, 4 °C), and the supernatant 
was collected for immunoprecipitation.
Invasion assay. Invasion assays were performed by using the CytoSelect™ Cell 
Invasion Assay (Cell Biolabs, Inc., San Diego, CA). The basement membrane layer 
of the cell culture inserts were rehydrated in 300 µl serum-free RPMI-1640, and 
2×106 cells were seeded into the upper area of the chambers in serum-free RPMI-
1640 with or without TGFβ. Lower wells of the invasion plates were filled with 
500 µl RPMI, supplemented with 10% FBS. Non-invasive cells were removed from 
the upper chamber and invasive cells were photographed by a Leica DMR light 
microscope, after staining with crystal violet cell stain solution. Colorimetric quan-
tification was performed by transfer inserts into 200 µl of extraction solution for 
10 min. Optical density (O.D.) at 560 nm was determined for extracts transferred to 
a 96-well microtiter plate using a plate reader.
Plasmids and DNA transfections. GFP-caTβRI was constructed by cloning full 
length caTβRI between the immediate early promoter of CMV and the EGFP cod-
ing sequence; the C-terminus of caTβRI was fused to the N-terminus of pEGFP-N3 
vector. The pcDNA3 and wt PKCζ plasmids were from Addgene. HA-caTβRI and 
HA-TβRI KR (kinase dead (KD) mutant) with HA fused to the C-terminus of 
TβRI, were kind gifts from P. ten Dijke (University of Leiden, The Netherlands). 
Expression vectors for C-terminally tagged HA-tagged G120I mutant for caTβRI 
were generated by PCR and the mutation was confirmed by sequencing. The 
caTβRI-E161A plasmid with HA fused to the C-terminus of TβRI was described 
before5. HA-TβRI with HA inserted between amino acid residues 27 and 28, was a 
kind gift from Dr S. Corvera (University of Massachusetts Medical School, Worces-
ter, USA). 3xHA-tagged wild-type ubiquitin, K48- and K63-only ubiquitin mutants 
were kind gifts from V.M Dixit (Genentech, San Francisco, CA). Expression vector 
for GST-TβRI fusion protein, encoding the complete cytoplasmic part (amino acid 
148-503) of ca TβRI (T204D) has been described previously28.
siRNA transfection. Twenty-one-base pair siRNA duplexes for TβRI (also known 
as ALK5), SMART pool siRNA for TRAF6 as previously described5, and a non-spe-
cific control siRNA, were synthesized by Dharmacon Research (Lafayette, CO). The 
sequence for TβRI siRNA duplex was 5′ AAC AUA UUG CUG CAA CCA GGA 
3′, and the non-specific duplex oligo 5′ AAC AGU CGC GUU UGC GAC UGG 3′. 
PKCζ siRNA (h2) was from Santa Cruz biotechnology. The siRNA was transfected 
with Oligofectamine (Invitrogen) according to the manufacturer’s protocol.
Expression analysis. Total RNA was isolated from cells using RNeasy Minikit 
(Qiagen) and Thermoscript RT–PCR System (Invitrogen) was used for the prepara-
tion of double-stranded cDNA. qRT–PCR was performed using Power SYBR 
Green PCR Mastermix (Applied Biosystems) with the Stratagene MX3000P. The 
following primers were used for qRT–PCR.
TβRI, forward primer (FP), TGTTGGTACCCAAGGAAAGC, reverse 
primer (RP), CACTCTGTGGTTTGGAGCAA; p300, FP, GGGACTAAC-
CAATGGTGGTG, RP, GTCATTGGGCTTTTGACCAT; SNAIL 1, FP, GAG-
CATACAGCCCCATCACT, RP, GGGTCTGAAAGCTTGGACTG; Smad7, FP, 
TCCTGCTGTGCAAAGTGTTC, RP, TCTGGACAGTCTGCAGTTGG; MMP 2, 
FP, AGGCCGACATCATGGTACTC, RP, GGTCAGTGCTGGAGAAGGTC; PAI 1, 
FP,CTCTCTCTGCCCTCACCAAC, RP, GTGGAGAGGCTCTTGGTCTG.
Chromatin immunoprecipitation. ChIPs were performed for three or more bio-
logical replicates. The ChIP protocol provided by Abcam, Cambridge UK was fol-
lowed. The chromatin was precipitated using the V22 rabbit antibody (Santa Cruz). 
After purification, the DNA was amplified using qRT-PCR to analyze ChIP DNA 
in triplicate. The following primers were used for ChIP; Snail1 forward primer, 
GGACTCAGGGAGACTCATGG, reverse primer, GGGTCTACGGAAA 
CCTCTGG.
Prostate cancer
Renal cell carcinoma
Bladder tumor
TβRI(V22) TβRI(H100)
Figure 8 | TRI ICD is localized in nucleus in different kinds of malignant 
tumours. Tumour tissues from prostate cancer, renal cell carcinoma 
and bladder tumour were stained with V22 and H100 antibodies, which 
recognize the intracellular and extracellular domain of TβRI, respectively. 
scale bar 20 µm.ARTICLE     
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Histology of human tumours. Tissue microarrays (TMAs) of malignant tissues, 
containing multiple samples from different patients with prostate cancer, renal cell 
carcinoma and bladder cancer produced by the Human Proteome Atlas (HPA) 
facility (http://www.proteinatlas.org) were stained using anti-TβRI antibodies (V22 
and H100). Pictures of stained TMA sections were taken with an ALTRA 20 soft 
imaging system and an Olympus BX45 microscope. Ethical permit to use decoded, 
tumour tissues for generation of tissue slides or TMA was granted by the Uppsala 
ethical review board in full agreement with the Swedish Ethical Review Act.
Statistical analysis. P values were calculated by Student’s two-tailed t-test or 
One-way ANOVA, as indicated in Figure legends. Analyses were performed in a 
Statistica software program. Values are expressed as mean ± s.d., of three or more 
independent experiments performed in triplicates, unless otherwise indicated.  
P values of  < 0.05 were considered statistically significant. 
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